高カルシウム血症治療の世界市場レポート 2025年

高カルシウム血症治療市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.5%で283億1,000万米ドルに成長します。予測期間中の成長は、慢性腎疾患の有病率の上昇、高血圧患者数の増加、新薬開発への投資の増加、患者の意識向上とエンパワーメント、政府の取り組みなどに起因すると考えられます。予測期間における主な動向としては、診断ツールや技術の強化、治療選択肢の発展、革新的な薬剤の開発、医療提供者間の協力関係の強化などが挙げられます。

副甲状腺疾患の有病率の増加は、高カルシウム血症治療市場の拡大を促進すると予想されます。副甲状腺疾患は副甲状腺に影響を及ぼし、副甲状腺ホルモン（PTH）の産生を通じて体内のカルシウム濃度を調整します。高齢化、認知度の向上、診断能力の向上、原発性副甲状腺機能亢進症や慢性腎臓病などの罹患率の増加など、これらの疾患の有病率上昇にはいくつかの要因が寄与しています。高カルシウム血症治療は、副甲状腺障害の管理において、カルシウム値の上昇を抑制し、腎臓結石や骨量減少などの合併症を予防し、全体的な代謝バランスを保つという重要な役割を担っています。例えば、米国の政府機関である国立衛生研究所（NIH）によると、米国における副甲状腺機能低下症は、10万人年あたり6.4～37人が罹患していると推定されており、その75％は甲状腺摘出術や頭頸部手術の合併症によるものです。その結果、副甲状腺障害の有病率の増加が高カルシウム血症治療市場の成長を後押ししています。

高カルシウム血症治療市場の主要企業は、カルシウムとリンの調節を強化し治療成績を向上させるため、リン酸結合剤などの革新的なソリューションの開発に注力しています。リン酸塩結合剤は、消化管でのリン酸塩吸収を防ぐ薬剤であり、腎臓病や高カルシウム血症患者の高リン酸塩濃度の管理に一般的に使用されています。例えば、2024年5月、インドの製薬会社Strides Pharma Science Limitedは、米国食品医薬品局（FDA）からセベラマー炭酸塩錠800mgの承認を取得しました。この錠剤は、食事のリン酸塩と結合してその吸収を防ぐことにより、慢性腎臓病患者の高リン血症を効果的に管理し、骨の健康維持とリン酸塩濃度の上昇に伴う心血管リスクの軽減に役立ちます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界高カルシウム血症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の高カルシウム血症治療市場：成長率分析
• 世界の高カルシウム血症治療市場の実績：規模と成長, 2019-2024
• 世界の高カルシウム血症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界高カルシウム血症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の高カルシウム血症治療市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビスホスホネート
• カルシトニン
• グルココルチコイド
• デノスマブ
• カルシウム刺激薬
• その他の薬物の種類
• 世界の高カルシウム血症治療市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性甲状腺機能亢進症
• 悪性腫瘍による高カルシウム血症
• その他の適応症
• 世界の高カルシウム血症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の高カルシウム血症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 世界の高カルシウム血症治療市場ビスホスホネートの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゾレドロン酸
• パミドロン酸
• アレンドロネート
• 世界の高カルシウム血症治療市場カルシトニンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サーモンカルシトニン
• 合成カルシトニン
• 世界の高カルシウム血症治療市場グルココルチコイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• デキサメタゾン
• ヒドロコルチゾン
• 世界の高カルシウム血症治療市場デノスマブの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• デノスマブ（単剤療法）
• デノスマブ併用療法
• 世界の高カルシウム血症治療市場カルシウム刺激薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シナカルセト
• エテルカルセチド
• 世界の高カルシウム血症治療市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 硝酸ガリウム
• ミトラマイシン

第7章 地域別・国別分析

• 世界の高カルシウム血症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の高カルシウム血症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 高カルシウム血症治療市場：競合情勢
• 高カルシウム血症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GSK plc
• Eli Lilly and Company
• Amgen Inc.
• Merck KGaA
• Fresenius Medical Care AG & Co. KGaA
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Ipsen SA
• Kyowa Kirin Co. Ltd.
• Hikma Pharmaceuticals plc
• Endo International plc
• OPKO Health Inc.
• Ferring Pharmaceuticals A/S
• Rockwell Medical Inc.
• Strides Pharma Science Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 高カルシウム血症治療市場2029：新たな機会を提供する国
• 高カルシウム血症治療市場2029：新たな機会を提供するセグメント
• 高カルシウム血症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hypercalcemia treatment involves the medical management of elevated calcium levels in the blood caused by conditions such as hyperparathyroidism or malignancies. Treatment options include hydration, diuretics, bisphosphonates, and calcitonin to lower calcium levels and prevent complications. It is utilized in both emergency and long-term care settings to prevent kidney damage, neurological issues, and cardiac dysfunction.

The primary drug types for hypercalcemia treatment include bisphosphonates, calcitonin, glucocorticoids, denosumab, calcimimetics, and others. Bisphosphonates are a class of medications that treat bone diseases by inhibiting osteoclast activity, reducing bone breakdown. The treatment is indicated for conditions such as primary hyperparathyroidism, hypercalcemia of malignancy, and others. These medications are distributed through various channels, including hospitals, retail pharmacies, and online pharmacies, and are used by multiple end-users, such as hospitals and clinics.

The hypercalcemia treatment market research report is one of a series of new reports from The Business Research Company that provides hypercalcemia treatment market statistics, including the hypercalcemia treatment industry global market size, regional shares, competitors with the hypercalcemia treatment market share, detailed hypercalcemia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the hypercalcemia treatment industry. This hypercalcemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hypercalcemia treatment market size has grown rapidly in recent years. It will grow from $16.44 billion in 2024 to $18.34 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth during the historic period can be attributed to increasing awareness of hypercalcemia, a growing geriatric population, a rise in cancer cases, greater disease awareness, and the increasing prevalence of parathyroid disorders.

The hypercalcemia treatment market size is expected to see rapid growth in the next few years. It will grow to $28.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth during the forecast period can be attributed to the rising prevalence of chronic renal disease, the increasing number of patients with hypertension, higher investment in developing novel medications, greater awareness and patient empowerment, and government initiatives. Key trends in the forecast period include enhanced diagnostic tools and techniques, advancements in treatment options, the development of innovative drugs, and increased collaborations among healthcare providers.

The increasing prevalence of parathyroid disorders is expected to drive the expansion of the hypercalcemia treatment market. Parathyroid disorders affect the parathyroid glands, which regulate calcium levels in the body through the production of parathyroid hormone (PTH). Several factors contribute to the rising prevalence of these disorders, including an aging population, increased awareness, improved diagnostic capabilities, and a growing incidence of conditions such as primary hyperparathyroidism and chronic kidney disease. Hypercalcemia treatment plays a crucial role in managing parathyroid disorders by controlling elevated calcium levels, preventing complications such as kidney stones and bone loss, and maintaining overall metabolic balance. For example, according to the National Institute of Health (NIH), a US-based government agency, hypoparathyroidism in the United States is estimated to affect 6.4 to 37 per 100,000 person-years, with 75% of cases resulting from complications of thyroidectomy or head and neck surgery. As a result, the increasing prevalence of parathyroid disorders is fueling the growth of the hypercalcemia treatment market.

Leading companies in the hypercalcemia treatment market are focusing on developing innovative solutions, such as phosphate binders, to enhance calcium and phosphorus regulation and improve treatment outcomes. Phosphate binders are medications that prevent phosphate absorption in the digestive tract and are commonly used to manage high phosphate levels in patients with kidney disease or hypercalcemia. For instance, in May 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, received approval from the United States Food and Drug Administration (FDA) for its Sevelamer Carbonate Tablets, 800 mg. These tablets effectively manage hyperphosphatemia in patients with chronic kidney disease by binding dietary phosphate and preventing its absorption, helping to maintain bone health and reduce cardiovascular risks associated with elevated phosphate levels.

In December 2024, Teijin Pharma Limited, a Japan-based pharmaceutical company, partnered with Ascendis Pharma A/S to introduce innovative prodrug technology for hypoparathyroidism treatment. This collaboration enables Teijin to utilize advanced prodrug technology that provides sustained PTH levels, potentially offering a more effective and convenient treatment option compared to existing therapies. Ascendis Pharma A/S, a Denmark-based company, specializes in developing innovative prodrugs for treating hypoparathyroidism in adults.

Major players in the hypercalcemia treatment market are Pfizer Inc., Roche Holding AG, AbbVie Inc., AstraZeneca plc, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Merck KGaA, Fresenius Medical Care AG & Co. KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ipsen SA, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, OPKO Health Inc., Ferring Pharmaceuticals A/S, Rockwell Medical Inc., Strides Pharma Science Limited.

North America was the largest region in the hypercalcemia treatment market in 2024. The regions covered in hypercalcemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypercalcemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypercalcemia treatment market consists of revenues earned by entities through services such as surgical treatment, dietary modifications, and bisphosphonates. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypercalcemia treatment market also includes sales of metabolic testing devices, body composition analyzers, and wearable fitness trackers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypercalcemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypercalcemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hypercalcemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypercalcemia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Bisphosphonates; Calcitonin; Glucocorticoids; Denosumab; Calcimimetics; Other Drug Types
• 2) By Indication: Primary Hyperthyroidism; Hypercalcemia Of Malignancy; Other Indications
• 3) By Distribution Channel: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End-Users: Hospitals; Clinics
• Subsegments:
• 1) By Bisphosphonates: Zoledronic Acid; Pamidronate; Alendronate
• 2) By Calcitonin: Salmon Calcitonin; Synthetic Calcitonin
• 3) By Glucocorticoids: Prednisone; Dexamethasone; Hydrocortisone
• 4) By Denosumab: Denosumab (Monotherapy); Denosumab Combination Therapy
• 5) By Calcimimetics: Cinacalcet; Etelcalcetide
• 6) By Other Drug Types: Gallium Nitrate; Mithramycin
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; AbbVie Inc.; AstraZeneca plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hypercalcemia Treatment Market Characteristics

3. Hypercalcemia Treatment Market Trends And Strategies

4. Hypercalcemia Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hypercalcemia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hypercalcemia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hypercalcemia Treatment Market Growth Rate Analysis
• 5.4. Global Hypercalcemia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hypercalcemia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hypercalcemia Treatment Total Addressable Market (TAM)

6. Hypercalcemia Treatment Market Segmentation

• 6.1. Global Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bisphosphonates
• Calcitonin
• Glucocorticoids
• Denosumab
• Calcimimetics
• Other Drug Types
• 6.2. Global Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Hyperthyroidism
• Hypercalcemia of Malignancy
• Other Indications
• 6.3. Global Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Hypercalcemia Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• 6.5. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Bisphosphonates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zoledronic Acid
• Pamidronate
• Alendronate
• 6.6. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Calcitonin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Salmon Calcitonin
• Synthetic Calcitonin
• 6.7. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Glucocorticoids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Dexamethasone
• Hydrocortisone
• 6.8. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Denosumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Denosumab (Monotherapy)
• Denosumab Combination Therapy
• 6.9. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Calcimimetics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cinacalcet
• Etelcalcetide
• 6.10. Global Hypercalcemia Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gallium Nitrate
• Mithramycin

7. Hypercalcemia Treatment Market Regional And Country Analysis

• 7.1. Global Hypercalcemia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hypercalcemia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hypercalcemia Treatment Market

• 8.1. Asia-Pacific Hypercalcemia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hypercalcemia Treatment Market

• 9.1. China Hypercalcemia Treatment Market Overview
• 9.2. China Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hypercalcemia Treatment Market

• 10.1. India Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hypercalcemia Treatment Market

• 11.1. Japan Hypercalcemia Treatment Market Overview
• 11.2. Japan Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hypercalcemia Treatment Market

• 12.1. Australia Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hypercalcemia Treatment Market

• 13.1. Indonesia Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hypercalcemia Treatment Market

• 14.1. South Korea Hypercalcemia Treatment Market Overview
• 14.2. South Korea Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hypercalcemia Treatment Market

• 15.1. Western Europe Hypercalcemia Treatment Market Overview
• 15.2. Western Europe Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hypercalcemia Treatment Market

• 16.1. UK Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hypercalcemia Treatment Market

• 17.1. Germany Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hypercalcemia Treatment Market

• 18.1. France Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hypercalcemia Treatment Market

• 19.1. Italy Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hypercalcemia Treatment Market

• 20.1. Spain Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hypercalcemia Treatment Market

• 21.1. Eastern Europe Hypercalcemia Treatment Market Overview
• 21.2. Eastern Europe Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hypercalcemia Treatment Market

• 22.1. Russia Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hypercalcemia Treatment Market

• 23.1. North America Hypercalcemia Treatment Market Overview
• 23.2. North America Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hypercalcemia Treatment Market

• 24.1. USA Hypercalcemia Treatment Market Overview
• 24.2. USA Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hypercalcemia Treatment Market

• 25.1. Canada Hypercalcemia Treatment Market Overview
• 25.2. Canada Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hypercalcemia Treatment Market

• 26.1. South America Hypercalcemia Treatment Market Overview
• 26.2. South America Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hypercalcemia Treatment Market

• 27.1. Brazil Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hypercalcemia Treatment Market

• 28.1. Middle East Hypercalcemia Treatment Market Overview
• 28.2. Middle East Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hypercalcemia Treatment Market

• 29.1. Africa Hypercalcemia Treatment Market Overview
• 29.2. Africa Hypercalcemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hypercalcemia Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hypercalcemia Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hypercalcemia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Hypercalcemia Treatment Market Competitive Landscape
• 30.2. Hypercalcemia Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Hypercalcemia Treatment Market Other Major And Innovative Companies

• 31.1. GSK plc
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Merck KGaA
• 31.5. Fresenius Medical Care AG & Co. KGaA
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Sandoz International GmbH
• 31.8. Ipsen SA
• 31.9. Kyowa Kirin Co. Ltd.
• 31.10. Hikma Pharmaceuticals plc
• 31.11. Endo International plc
• 31.12. OPKO Health Inc.
• 31.13. Ferring Pharmaceuticals A/S
• 31.14. Rockwell Medical Inc.
• 31.15. Strides Pharma Science Limited

32. Global Hypercalcemia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypercalcemia Treatment Market

34. Recent Developments In The Hypercalcemia Treatment Market

35. Hypercalcemia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Hypercalcemia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hypercalcemia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hypercalcemia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer